Eli Lilly's (LLY) obesity drug Orforglipron missed market expectations in its phase 3 ATTAIN-1 trial, showing 11.2% average weight loss versus the expected 14% to 15%, Deutsche Bank said in a note Friday.
The trial's 10% treatment-related dropout rate was higher than seen with semaglutide, despite lower rates of nausea, constipation, diarrhea, and vomiting, the investment firm said.
Results from obesity studies contrast with stronger performance in type 2 diabetes trials, creating a mixed overall picture for the drug, according to Deutsche Bank.
Eli Lilly shares could face pressure despite a strong Q2 earnings beat and guidance raise, according to the note.
The data likely support US Food and Drug Administration approval, but the drug may require deeper-than-expected price discounts to compete commercially, the Deutsche Bank analysts noted.
Deutsche Bank has buy rating on Eli Lilly with a $1,010 price target.
Price: 639.23, Change: -1.63, Percent Change: -0.25
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。